COVID-19 vaccine: Govt issues company-wise supply plan of Remdesivir to states, UTs
The companies have been instructed to ensure timely supplies of Remdesivir to all states/UTs strictly as per the supply plan
BusinessToday.In | May 8, 2021 | Updated 15:08 IST
The development comes in continuation to the allocation of Remdesivir to states/UTs done on Friday, May 7
The Centre on Saturday, May 8, issued a company-wise supply plan of antiviral drug Remdesivir to states and Union Territories (UTs). Remdesivir is a key drug used in the treatment of COVID-19 patients. The company-wise supply plan of Remdesivir for the period April 21 to May 16 has been issued to states/UTs, read an official statement by the Ministry of Chemicals and Fertilizers.
To ensure smooth supply of remdesivir used in the treatment of COVID-19 across the country, the allocation of the antiviral drug to the states and union territories has been made up to May 16, Union Chemicals and Fertilisers Minister Sadananda Gowda said on Friday. The production capacity of remdesivir has been increased to 1.03 crore vials per month, up from 38 lakh vials per month earlier, the minister had said on Tuesday. Considering the requirement of Remdesivir in every state and ensuring its adequate availability, allocation of #Remdesivir has been made upto 16th May 2021. This will ensure smooth supply of Remdesivir across country so that no patient face difficulty in this #pandemic time, Gowda said in a tweet.
Allocation of remdesivir made up to May 16 to ensure adequate availability: Sadananda Gowda
The allotment is being made for the states/UTs and it is the state governments and UTs that have to monitor proper distribution.
Share Via Email
| A+A A- By PTI
NEW DELHI: To ensure smooth supply of remdesivir used in the treatment of COVID-19 across the country, the allocation of the antiviral drug to the states and union territories has been made up to May 16, Union Chemicals and Fertilisers Minister Sadananda Gowda said on Friday.
The production capacity of remdesivir has been increased to 1.03 crore vials per month, up from 38 lakh vials per month earlier, the minister had said on Tuesday.
The Union government has made an interim allocation of tocilizumab among the states, as a fresh limited stock of the drug used for the treatment of COVID-19 patients has arrived in the country. In a letter, Pharma Joint Secretary Navdeep Rinwa and Health and Family Welfare Ministry Director Rajiv Wadhawan said the drug went out of stock in the country a few weeks ago due to a sudden surge in its demand because of a sharp rise in COVID-19 cases in the country. Fresh limited stock of this drug has now been imported and is available with lone marketer company Cipla Ltd formarketing and distribution in the country, the letter said.